Results 171 to 180 of about 2,170,657 (312)

Epigenetic heterogeneity and plasticity in therapy‐induced tumor states through single‐cell multi‐omics

Molecular Oncology, EarlyView.
Single‐cell multi‐omics reveals epigenetic heterogeneity across therapy‐adaptive tumor states, including quiescent/dormant, drug‐tolerant persister, and EMT‐like phenotypes. By linking regulatory features with state‐associated biomarkers, these approaches inform biomarker‐guided therapeutic strategies for evolving tumors.
Hee Jung Kim, Hwiyeong Lee, Jin Hong, Daechan Park   +3 more
wiley   +1 more source

Combined Effect of Sarcopenia and Impaired Respiratory Function on All-Cause Death: A Nationwide Cohort Study. [PDF]

J Cachexia Sarcopenia Muscle
Wu C, Wu D, Li M, Lu S, Wang Y, Lan Y.
europepmc   +1 more source

National Violent Death Reporting System: Web Coding Manual: Version 6.0 [2022-01-18] [PDF]

Version 6.0, revision date: January 18, 2022The NVDRS Coding Manual is a reference document to be used for defining cases and variables, entering data, and checking data once they are entered.

core  

PAK1 activation drives divergent resistance mechanisms to aromatase inhibition and tamoxifen in a luminal: A breast cancer model

Molecular Oncology, EarlyView.
Breast cancer remains a major cause of cancer death in women, frequently developing endocrine therapy resistance. This study demonstrates that upregulated p21‐activated kinase 1 (PAK1) activity drives resistance to tamoxifen and long‐term estrogen deprivation in ER+ breast cancer models.
Luisa Schwarzmüller, Janina Müller, Efstathios‐Iason Vlachavas, Lukas Beumers, Lena Fleischhacker, Sara Burmester, Angelika Wörner, Sabine Karolus, Dominic Helm, Cindy Körner, Stefan Wiemann   +10 more
wiley   +1 more source

Inhibition of cyclin‐dependent kinases 12/13 using CT7439 as a treatment for colorectal cancer with CDK12 upregulation

Molecular Oncology, EarlyView.
The proposed mechanism of action for the CDK12/13 inhibitor and cyclin K degrader, CT7439. CDK12/13 inhibition interrupts transcription elongation, leading to increased DNA damage that results in cell death. This agent is a potentially novel treatment option for patients with colorectal cancer. Created in BioRender. Cyclin‐dependent kinase (CDK) 12 and
Wylie K. Watlington, Divya L. Dayanidhi, Mohammad Zokaasadi, John B. Mantyh, Pelumi D. Olawuni, Gabrielle Rupprecht, Jeremy M. Force, Shannon McCall, Ashwani K. Bahl, David S. Hsu, Jason A. Somarelli   +10 more
wiley   +1 more source

Associations between Abdominal Aortic Aneurysm with Cardiovascular Disease and All Cause Death in the Atherosclerosis Risk in Communities (ARIC) Study. [PDF]

Eur J Vasc Endovasc Surg
Edsall AE, Lutsey PL, Hong CP, Kucharska-Newton A, Mok Y, Matsushita K, Pankow JS, Folsom AR, Tang W.   +8 more
europepmc   +1 more source

Dog ownership, glycaemic control and all-cause death in patients with newly diagnosed type 2 diabetes: a national cohort study. [PDF]

Front Public Health, 2023
Rådholm K, Af Geijerstam P, Woodward M, Chalmers J, Hellgren M, Jansson S, Rolandsson O.   +6 more
europepmc   +1 more source

Mortality by occupation, industry, and cause of death; 24 reporting states, 1984-1988 [PDF]

"Health departments from 24 states have provided occupational and industry coded death certificate data for at least 1 year from 1984 through 1988 for analysis.

core  

In vitro and in silico modelling of ROS1‐positive non‐small cell lung cancer reveals fusion‐dependent tyrosine kinase inhibitor responses

Molecular Oncology, EarlyView.
Drug resistance limits treatment success in a subset of lung cancers driven by ROS1 gene alterations. Using patient‐derived cells and computer simulations, we studied three key mutations and how they affect five targeted drugs. The mutations reduced drug effectiveness in different ways by altering protein structure and behavior.
Farhan Ul Haq, Marc Terrones, Felicia Rodrigues Fortes, Anne Schepers, Alessia Denis, Christophe Deben, Ken Op de Beeck, Guy Van Camp, Geert Vandeweyer   +8 more
wiley   +1 more source

C-reactive protein and prospective cardiometabolic risk: observational and Mendelian randomization study of ischemic stroke and all-cause death. [PDF]

Cardiovasc Diabetol
Rolver MG, Emanuelsson F, Nordestgaard BG, Benn M.   +3 more
europepmc   +1 more source